New R&D collaboration to take on superbug challenge

Hamburg-based drug development firm Evotec (EVR: EVT) has formed a new partnership with the Global Antibiotic Research and Development Partnership (GARDP) to tackle the growing threat of antimicrobial resistance.

The collaboration will bring together GARDP's clinical expertise and sustainable access commitment with Evotec's technology and its collection of bacterial pathogens.

The partnership focuses on accelerating the development of first-in-class antibiotic treatments for hard-to-treat bacterial infections, with the development of a joint pipeline of candidates.